The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes; Tim Spelman; Guillermo Izquierdo; Maria Trojano; Alessandra Lugaresi; Francois Grand'Maison; Eva Havrdova; Dana Horakova; Cavit Boz; Celia Oreja-Guevara; Raed Alroughani; Gerardo Iuliano; Pierre Duquette; Marc Girard; Murat Terzi; Raymond Hupperts; Pierre Grammond; Thor Petersen; Ricardo Fernandez-Bolanos; Marcela Fiol; Eugenio Pucci; Jeannette Lechner-Scott; Freek Verheul; Edgardo Cristiano; Vincent Van Pesch; Tatjana Petkovska-Boskova; Fraser Moore; Ilya Kister; Roberto Bergamaschi; Maria Laura Saladino; Mark Slee; Michael Barnett; Maria Pia Amato; Cameron Shaw; Neil Shuey; Carolyn Young; Orla Gray; Ludwig Kappos; Helmut Butzkueven; Tomas Kalincik; Vilija Jokubaitis

Journal article

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Matthew Warrender-Sparkes, Tim Spelman, Guillermo Izquierdo, Maria Trojano, Alessandra Lugaresi, Francois Grand'Maison, Eva Havrdova, Dana Horakova, Cavit Boz, Celia Oreja-Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernandez-Bolanos, Marcela Fiol Show all

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2016

DOI: 10.1177/1352458515594041

Download PDF

Abstract

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). METHODS: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. RESULTS: A total of 2640 patients commenced immunomodulatory therapy. Following the intr..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author Surgery - St Vincent's Hospital

Helmut Butzkueven Author Medicine - Royal Melbourne Hospital

Tomas Kalincik Author Medicine - Royal Melbourne Hospital

Related Projects (4)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by NHMRC

Awarded by Multiple Sclerosis Research Australia Postdoctoral Fellowship

Funding Acknowledgements

The work was supported by the NHMRC Early Career Fellowship [1071124], Multiple Sclerosis Research Australia Postdoctoral Fellowship [11-054], NHMRC Career Development Award [628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis and BioCSL.